

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, correct certain typographical errors and to otherwise place the claims in an appropriate U.S. format. Specifically:

- Claim 1 has been amended to correct a typographical error in the spelling of “substituents” and the spelling of phosphonoxy has been corrected in the definition of R<sup>10</sup>;
- Claim 4 has been amended to correct a typographical error and to remove the multiple dependency;
- Claims 5-9 inclusive have been amended to remove the multiple dependencies;
- Claim 10 has been amended to correct a typographical error in the names of the 2<sup>nd</sup> and 4<sup>th</sup> compounds, a hyphen has been added where it had been omitted;
- Claim 11 has been amended to correct the multiple dependency;
- Claims 12-15 have been cancelled;
- Claims 16-18 have been amended to make the language consistent with other claims;
- Claim 19 has been added, this is based on original claim 14;
- Claim 20 has been added, this is the subject matter of claim 1 incorporating the subject matter of claims 3, 4 and 9, basis for this claim is original claims 1, 3, 4 and 9;
- Claim 21 has been added, basis for this claim is to be found on page 11 line 16-34;
- Claim 22 has been added, basis for this claim is to be found on page 12 line 17-34; and
- Claim 23 has been added, basis for this claim is original claim 11.

No new matter has been added by these amendments and the above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100936 1P-US.

Respectfully submitted,



---

Name: Lucy Padget  
Dated: June 17, 2005  
Reg. No.: Limited Recognition  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 01760